Effects of intravenously administered C-type natriuretic peptide in humans

Comparison with atrial natriuretic peptide

T. Igaki, Hiroshi Itoh, S. I. Suga, N. Hama, Y. Ogawa, Y. Komatsu, J. Yamashita, K. Doi, T. Chun, K. Nakao

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80%, +160 ± 100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalHypertension Research - Clinical and Experimental
Volume21
Issue number1
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

C-Type Natriuretic Peptide
Atrial Natriuretic Factor
Natriuretic Peptides
Blood Pressure
Injections
Aldosterone
Diuretics
Blood Vessels
Healthy Volunteers
Endothelial Cells
Heart Rate

Keywords

  • Atrial natriuretic peptide (ANP)
  • Blood pressure
  • C-type natriuretic peptide (CNP)
  • Guanosine 3',5'-cyclic monophosphate (cGMP)
  • Natriuresis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of intravenously administered C-type natriuretic peptide in humans : Comparison with atrial natriuretic peptide. / Igaki, T.; Itoh, Hiroshi; Suga, S. I.; Hama, N.; Ogawa, Y.; Komatsu, Y.; Yamashita, J.; Doi, K.; Chun, T.; Nakao, K.

In: Hypertension Research - Clinical and Experimental, Vol. 21, No. 1, 1998, p. 7-13.

Research output: Contribution to journalArticle

Igaki, T, Itoh, H, Suga, SI, Hama, N, Ogawa, Y, Komatsu, Y, Yamashita, J, Doi, K, Chun, T & Nakao, K 1998, 'Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide', Hypertension Research - Clinical and Experimental, vol. 21, no. 1, pp. 7-13.
Igaki, T. ; Itoh, Hiroshi ; Suga, S. I. ; Hama, N. ; Ogawa, Y. ; Komatsu, Y. ; Yamashita, J. ; Doi, K. ; Chun, T. ; Nakao, K. / Effects of intravenously administered C-type natriuretic peptide in humans : Comparison with atrial natriuretic peptide. In: Hypertension Research - Clinical and Experimental. 1998 ; Vol. 21, No. 1. pp. 7-13.
@article{11c974b724ed435d80d57eee097b5acc,
title = "Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide",
abstract = "We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80{\%}, +160 ± 100{\%} over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22{\%} reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.",
keywords = "Atrial natriuretic peptide (ANP), Blood pressure, C-type natriuretic peptide (CNP), Guanosine 3',5'-cyclic monophosphate (cGMP), Natriuresis",
author = "T. Igaki and Hiroshi Itoh and Suga, {S. I.} and N. Hama and Y. Ogawa and Y. Komatsu and J. Yamashita and K. Doi and T. Chun and K. Nakao",
year = "1998",
language = "English",
volume = "21",
pages = "7--13",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effects of intravenously administered C-type natriuretic peptide in humans

T2 - Comparison with atrial natriuretic peptide

AU - Igaki, T.

AU - Itoh, Hiroshi

AU - Suga, S. I.

AU - Hama, N.

AU - Ogawa, Y.

AU - Komatsu, Y.

AU - Yamashita, J.

AU - Doi, K.

AU - Chun, T.

AU - Nakao, K.

PY - 1998

Y1 - 1998

N2 - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80%, +160 ± 100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

AB - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80%, +160 ± 100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

KW - Atrial natriuretic peptide (ANP)

KW - Blood pressure

KW - C-type natriuretic peptide (CNP)

KW - Guanosine 3',5'-cyclic monophosphate (cGMP)

KW - Natriuresis

UR - http://www.scopus.com/inward/record.url?scp=0031957394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031957394&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 7

EP - 13

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -